Skip to content
Log in
Sponsored AI AM CLAUDE, A Beginner's Guide: Learn the basics of working with AI AI AM CLAUDE, A Beginner's Guide: Learn the basics of working with AI

Author

P. Dobrowolski

View on Semantic Scholar

5 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Plasma Lipidomic Phenotype Associated with Pathogenic LDLR Variants in Familial Hypercholesterolemia

Familial hypercholesterolemia (FH) is caused by an impaired ability to clear circulating low-density lipoprotein (LDL-C) particles due to a defective low-density lipoprotein receptor (LDLR). FH significantly increases cardiovascular risk (CVR). Although conventional lipid parameters are essential for diagnosing FH, the...

Joanna Waś, Aleksander Prejbisz, M. Niedolistek et al. · 0 citations
Open access Sep 2026

Association of lipoprotein(a) with the angiographic extent of coronary artery disease and selected angiographic findings in patients with acute coronary syndromes.

Elevated Lp(a) concentrations were independently associated with the angiographic extent of coronary artery disease in patients with acute coronary syndromes, including multivessel disease and chronic total occlusions, including multivessel disease and chronic total occlusions.

Michał Miszczak, Beata Mokrauz, P. Piwowarczyk et al. · 0 citations
Open access Oct 2026

Diet and nutrition in obesity treated with incretin-based therapies: A scientific statement of the Polish Society of Dietetics.

Incretin-based therapies, including glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual GIP/GLP-1 receptor agonists, have transformed obesity treatment by producing substantial weight loss and improving cardiometabolic outcomes. However, their therapeutic effects are accompanied by nutritional challenges, in...

A. Kwaśny, Małgorzata Słoma-Krześlak, G. Kostelecki et al. · 0 citations
Review Open access Aug 2026

Lipoprotein(a) as a Cardiovascular Risk Factor: Clinical Significance and Therapeutic Perspectives

Lp(a) may soon shift from a “silent threat” to a precise, actionable target in cardiovascular prevention, according to a review of the current evidence, which highlights gaps in knowledge, and discusses emerging therapeutic strategies.

Michał Miszczak, P. Piwowarczyk, G. Sobieszek et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.